The evolving genomic landscape of acute lymphoblastic leukemia (ALL): subtypes, genes and targets
What are the practical considerations for monoclonal antibody infusion?
The important issues to consider when deciding when a multiple myeloma patient must start treatment
The future is bright for hematological oncology: promising areas for 2018 and beyond
Molecular modelling of drug efficacy in multiple myeloma
Brian Van Ness